Meeting
2022 ASCO Annual Meeting
Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774].
Authors
Wesley R Armstrong
Ahmanson Translational Theranostics Division, University of California, Los Angeles, CA
Wesley R Armstrong , Amar Upadhyaya Kishan , Kiara M Booker , Wolfgang Peter Fendler , Thomas A. Hope , Nicholas George Nickols , Johannes Czernin , Jeremie Calais
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
NCT03582774
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5028)
DOI
10.1200/JCO.2022.40.16_suppl.5028
Abstract #
5028
Poster Bd #
212
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
![Randomized prospective phase 3 trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].](https://d201v5jt9ylckg.cloudfront.net/239/13724/178070/178070_poster_pv.jpg)
Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
First Author: Jeremie Calais
Poster
2019 Genitourinary Cancers Symposium
![Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].](https://d201v5jt9ylckg.cloudfront.net/237/14160/170145/170145_poster_pv.jpg)
Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
First Author: Jeremie Calais
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk of biochemical recurrence (BCR) after radical prostatectomy (RP) in the ongoing phase 3 PRIMORDIUM study.
First Author: Boris A. Hadaschik
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang